FDA reviewing diabetes drugs over pancreatic risks

LONDON (MarketWatch) — The Food and Drug Administration has non-stop a reserve examination of diabetes drugs from Merck Co. and Bristol-Myers Squibb Co. on concerns that they could lead to pancreatic diseases, The Wall Street Journal reported late Thursday. The FDA pronounced it's seeking some-more information about how those companies' drugs that are used to provide type-2 diabetes could trigger inflammation of a pancreas and presumably means precancerous dungeon changes, a WSJ reported. But a FDA also pronounced it hadnj't come to a end that those drugs "may means or minister to a growth of pancreatic cancer." Medical researchers have in new years cited problems with Bristol-Myers's Byetta and Bydureon and Merck's Januvia, a news said.

Read full article: http://www.independent.co.uk/news/science/scientists-find-habitable-tau-ceti-planet-8424912.html

Related Posts

• FDA reviewing diabetes drugs over pancreatic risks
• Security army conflict insurgent village
• Are Tropical Forests Immune To Global Warming?
• SLIDESHOW: Astronomers betray camera that will find additional human life
• ACCC proposes Telstra indiscriminate ADSL cuts
• China sell-off hits internal shares
• Chinese villagers during fight with army over land deal
• I married Daniel Craig during 40 – it was one of a best years of my life
• Working moms, don’t try to be perfect
• Falklands referendum: Voters select to sojourn UK territory
• Healthy patients who practice frequently and equivocate greasy dishes ‘should be quick …
• Brian McDermott sacked by Reading – players sensitive by content summary …
• Samsung offers look during what might be new Galaxy S4
• Jobs marketplace given lift by banks employing to understanding with PPI scandal
• Vatican government a pivotal emanate during conclave

Source:
http://www.news.ezonearticle.com/2013/03/15/fda-reviewing-diabetes-drugs-over-pancreatic-risks/